New Immundiagnostik Test Simplifies Detecting, Measuring Unintentional Gluten Consumption
Summary
Manchester, NH, April 05, 2022 --( PR.com )-- Immundiagnostik, Inc., the North American subsidiary of Immundiagnostik AG, has collaborated with Labcorp (NYSE: LH), a leading global life sciences company, to help individuals detect and quantify unintentional gluten consumption by utilizing a new fecal gluten test. The quantitative test developed by Immundiagnostik and offered exclusively through Labcorp detects the presence of gluten in a patient’s stool sample and has a high sensitivity and specificity.“This collaboration with Labcorp has allowed us to provide a reliable and accurate test to further advance the current methods of detecting traces of gluten,” says Terance Fisher, chief operations officer of Immundiagnostik, Inc. “As a leading developer of gastrointestinal immunoassays and diagnostic tools for laboratories, Immundiagnostik is committed to helping improve patient outcomes in partnership with industry leaders such as Labcorp.”Unlike other products for monitoring unintended exposure, the Immundiagnostik test measures the amount of gluten detected in a sample. In one study of celiac patients on a gluten-free diet, 67% of participants with persistent symptoms had detectable levels of gluten in their stool samples. The company develops and manufactures innovative immunoassays and diagnostic detection methods for clinical and research laboratories. An extensive product offering is continuously refueled by a rich pipeline of exclusive developments supported by collaborations with leading clinical and research laboratories, biopharma companies, and a global network of key scientific pioneers.Immundiagnostik, Inc. works to discover solutions on the cutting edge of science and develops reliable diagnostic tools for research and clinical laboratories to apply toward improving patient care.